Processes and Requirements of Peer Review of Toxicological Pathology Based on GLP

doi:10.19803/j.1672-8629.2020.11.09

Abstract

Abstract: Objective To explore the processes and requirements of peer review of toxicological pathology in order to ensure more effective peer review in China. Methods With "toxicological pathology" "peer review process" "peer review requirements" and "pathologist" as key words, the China HowNet、Wanfang、CNKI and Pubmed databases from December 1998 to December 2018 were searched to retrieve articles related to peer review processes and requirements of toxicological pathology before the content of these articles was analyzed and summarized. Results and Conclusion A total of 12,657 pieces of related literature were retrieved and 22 of them were screened out. Through literature review, it was concluded that the processes and requirements of peer review in the field of toxicological pathology were generally similar between China and other countries. However, in China's codes regarding peer review of toxicological pathology, only regulations are available, without any interpretations of these regulations. Peer review of toxicological pathology has been implemented abroad, and many regulations have been updated.

Key words: toxicological pathology, peer review process, peer review requirements, pathologists

CLC Number:

R994.1

LI Jian Hua, ZHAO Liang You, LIU Shu Min. Processes and Requirements of Peer Review of Toxicological Pathology Based on GLP[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 790-793.

References

[1] Liu L,Li B.Non clinical safety of vaccines[J].Chinese Journal of New Drugs(中国新药杂志),2018,27(21):2472-2481.
[2] Yin JY,Wang HM,Qu WS, et al.Peer review of toxicity pathology based on the new "quality management standard for non clinical research of drugs"[J].Journal of International Pharmaceutical Research(国际药学研究杂志),2017,44(12):1085-1088.
[3] Boorman GA, Haseman JK, Waters MD, et al.Quality Review Procedures Necessary for Rodent PathologyDatabases and Toxico-genomic Studies:The National Toxicology Program Experience[J]. Toxicol Pathol,2002,30(1):88-92.
[4] Mann PC and Hardisty JH.Pathology working groups[J].Toxicol Pathol, 2014,42(1): 283-284.
[5] Wang JN,Cao C.Discussion on standardization of pathology department in GLP institution[J].Drug Evaluation Research(药物评价研究),2011,34(4):241-243.
[6] Standardization Administration of China.GB/T 22278-2008Principles of good laboratory practice(GB/T 22278-2008良好实验室规范原则)[M].Beijing: Standards Press of China,2008:8.
[7] Melnick R,Lucier G,Wolfe M,et al.Summary of the National Toxicology Program′s report of the endocrine disruptors low-dose peer review[J]. Environ Health Perspect,2002,110(4):427-431.
[8] Certification and Accreditation Administration of the Pe. RB/T193-2015 Guidelines for the application of good laboratory practice in peer review of histopathology (RB/T193-2015良好实验室规范在组织病理学同行评议中的应用指南)[M].Beijing: Standards Press of China,2016:4.
[9] Liang AH,Han JY,Chen SL,et al.Quality and safety considerations of classical Chinese medicine prescriptions[J].China Food Drug Admi-nistration(中国食品药品监管),2018(6):4-10.
[10] Ren SL,Peng L,Cheng SW,et al.Efficacy and safety of fluorouracil combined with paracetamol in the treatment of knee osteoarthritis[J]. China Pharmacy(中国药房),2019,30(2):249-252.
[11] Zhang CL,Wang XC,Wang H,et al.Clinical observation of febuxostat in the treatment of type 2 diabetic nephropathy with hyperuricemia[J]. China Pharmacy(中国药房),2018,29(4):501-505.
[12] Yoshitomi.Peer review in toxicologic histopathology: its necessity, type and procedure[J].Toxicol Sci,1998, 23(Supplement 1):1-9.
[13] McLennan, Ludvik, Chambers, Frydenberg.Work after prostate cancer: a systematic review[J]. Cancer Surviv, 2019,13(2):282-291.
[14] Lv JJ,Qu Z,Huo GT.Interpretation of guidelines for GLP requi-rements of OECD histopathology peer review[J].Chinese Pharma-ceutical Affairs(中国药事),2016,30(10): 968-976.
[15] Fikes JD, Patrick DJ, Francke S, et al.Scientific and Regulatory Policy Committee Review: Review of the Organisation for Economic Co-operation and Development (OECD) Guidance on the GLP Requirements for Peer Review of Histopathology[J]. Toxicol Pathol, 2015,43(7):907-914.
[16] Gupta,Rispin,Stitzel,Coecke,Harbell. Ensuring quality of in vitro alternative test methods: issues and answers[J].Regul Toxicol Pharmacol, 2005, 43(3):219-24.
[17] Ward,Hardisty,Hailey,Streett.Peer review in toxicologic pathology[J]. Toxicol Pathol.1995, 23(2):226-34.
[18] Mann PC.Pathology peer review from the perspective of an external peer review pathologist[J].Toxicol Pathol,1996,24(5):650-653.
[19] Lv JJ,Huo GT,Lin Z,et al.Application of whole section image in histopathology peer review and pathology working group[J].Chinese Pharmaceutical Affairs(中国药事),2016,30(10):982-987.
[20] Crissman JW, Goodman DG, Hildebrandt PK, et al.Best practices guideline: toxicologic histopathology[J].Toxicol Pathol,2004, 32(1):126-131.
[21] Dong YS.Standardization construction and practice of toxicity pathology platform for drug safety evaluation[D].Academy of Military Medical Sciences,2012.
[22] Eighmy JJ.Study Pathologist Perspective of Pathology Peer Review[J]. Toxicol Pathol, 1996, 24(5): 647-649.